Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
Glioblastoma Multiforme
DRUG: Tamoxifen|DRUG: Etoposide
3 month progression-free survival, Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause., 3 months
One-year progression-free survival, Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause., 12 months|Overall survival, Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive., Median, 6-month, 1-year, and 2-year OS rates will be measured|Health-related quality-of-life status, Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients, Throughout study completion, up to 5 years.|Adverse events, This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded., Throughout the whole duration of the trial, up to 5 years
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.